34 results about "Radiation-induced lung injury" patented technology

Methods are disclosed for therapy of radiation-induced lung injury and other lung diseases using R-spondin1.

The invention relates to the technical field of medical science, in particular to new application of a ferroptosis inhibitor. The ferroptosis inhibitor is prepared from Liproxstatin-1, Ferrostatin-1,rosiglitazone, pioglitazone, troglitazone and Zileuton. The new application refers to that the inhibitor is applied to treating radiation-induced pulmonary injury diseases. The application has the advantages that (1) radioactive rays trigger radiation-induced pulmonary injury by mediating pulmonary alveoli epithelial cells to have ferroptosis, the ferroptosis specificity inhibitor can be used to prevent and treat radiation-induced pulmonary injury, and has the important meaning on development of new drug for preventing and treating radiation-induced pulmonary injury; and (2) it is found that radioactive rays can cause cell death through the mode of ferroptosis, and application of the ferroptosis inhibitor also has the significant theoretical meaning on guiding research for guiding radioactive rays to treat cancer mechanism.

The invention discloses a medicine for treating the radiation-induced pulmonary injury and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The medicine comprises the following raw materials constituting effective ingredients: hypoestes purpurea, arrowroot, siegesbeckia orientalis, crepis phoenix, dendrobium jenkinsii wall, ardisia japonica, Chinese alpine rush, wedelia chinensis, tangerine leaf, silverleaf cinquefoil root, pecan, gecko, wood betony, thesium chinense, trichosanthes kirilowii maxim and Chinese squill. The medicine is suitable in compatibility of selected medicines, conforms to the theory of traditional Chinese medicine and pharmacy and modern medicine and pharmacology, has the effects of nourishing yin, engendering fluid, moisturizing lung and relieving cough, activating blood and dissolving stasis and relieving swelling and pain, has an obvious treating effect on treatment of the radiation-induced pulmonary injury, and short in treatment course, allows fast effect, does not relapse after healing, has no toxic and side effects, is low in cost, can achieve the purpose of treating both symptoms and root causes in cost, and has special effect and practicability, thus being worthy of wide popularization and application in clinic.

A system and computation method is disclosed that identifies radiation-induced lung injury after radiation therapy using 4D computed tomography (CT) scans. After deformable image registration, the method segments lung fields, extracts functional and textural features, and classifies lung tissues. The deformable registration locally aligns consecutive phases of the respiratory cycle using gradient descent minimization of the conventional dissimilarity metric. Then an adaptive shape prior, a first-order intensity model, and a second-order lung tissues homogeneity descriptor are integrated to segment the lung fields. In addition to common lung functionality features, such as ventilation and elasticity, specific regional textural features are estimated by modeling the segmented images as samples of a novel 7th-order contrast-offset-invariant Markov-Gibbs random field (MGRF). Finally, a tissue classifier is applied to distinguish between the injured and normal lung tissues.

The invention relates to the technical field of medicines, and provides an application of glibenclamide or derivatives thereof in preparing medicines for preventing and protecting radiation-induced pulmonary injury. Furthermore, the invention also provides a pharmaceutical composition for preventing and protecting the radiation-induced pulmonary injury, wherein the pharmaceutical composition consists of the glibenclamide or derivatives thereof and pharmaceutically acceptable adjuvants. Based upon mice in-vivo experiments, the glibenclamide can obviously relieve a damage degree of blood vessel endothelium caused by radiation, so that increase in erythrocyte effusion is inhibited and the circumstance of pulmonary hemorrhage after the radiation is relieved; and through in-vivo cytological experiments, the glibenclamide can reduce an apoptosis rate of cells which accept the radiation and improve the circumstance of proliferation inhibition, showing that the glibenclamide, when applied in previous ways, can relieve the radiation-induced pulmonary injury of mice and reduce sensitivity of vascular endothelial cells to radiation; therefore, a new evidence is provided for prevention and protection of the radiation-induced pulmonary injury by virtue of the glibenclamide or derivatives thereof.

The invention discloses a traditional Chinese medicinal composition for treating radiation-induced lung injury. In traditional Chinese medicine, the radiation-induced lung injury belongs to 'consumptive lung disease' and 'gasp syndrome', and is caused by invasion of heat toxin, damage of collaterals in lung, intermingled phlegm and blood stasis, impairment of fluid and qi, and qi and yin injury. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicines capable of nourishing yin and clearing away heat, and moistening lung to arrest cough: rhizoma tupistrae chinensis, tendrilleaf solomonseal rhizome, unpleasant swallowwort herb, mountain oreas herb, brooklet anemone root, botrychiam ternatum, narrow-leaved lindernia, pleurotus albellus, paraphlonia, affine cudweed, laminated sanicle herb and mulberry leaf. The traditional Chinese medicinal composition is prepared into a decoction; a clinical test shows that total effective rate of the traditional Chinese medicinal composition is 97.1%, which is obviously excellent than that of a control group; the traditional Chinese medicinal composition is low in side effect.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine preparation for preventing and treating yin deficiency and lung heat radiation-induced lung injury. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30-90 parts of radix glehniae, 30-90 parts of fleshly scale leaf of lily, 15-45 parts of the root bark of white mulberry, 30-90 parts of rhizome of paris polyphylla, 10-30 parts of bulbus fritilariae, 15-45 parts of earthworm, 10-30 parts of herbaceous stem of ephedra, 15-45 parts of root-bark of tree peony, 10-30 parts of platycodon, 10-30 parts of semen armeniacae amarae, 10-30 parts of rhizoma anemarrhenae, 15-45 parts of holly leaves, 30-90 parts of rhizoma phragmitis, 15-45 parts of snake gourd fruits and 10-30 parts of liquorice root. The traditional Chinese medicine preparation is reasonable in design, avoids the effect of venous drugs and resulting side effects on the body of a patient, also avoids limitation caused by indication mastery, and overcomes the shortcomings of limitation of methods such as oral preparation of the traditional Chinese medicines to clinical observation and empirical antibiotics treatment.